Colorectum is the most common site of metastasis in ovarian cancer. Regarding intestinal surgery, there is controversy over whether to choose bowel resection or tumor removal, and currently, there are no prospective randomized controlled studies comparing the oncological safety of these two surgical approaches. This study is a prospective randomized trial aimed at comparing the efficacy of rectosigmoid resection versus rectosigmoid-preserving lesion excision in advanced ovarian cancer surgery.
Eligibility
Sex
FEMALE
Min age
18 Years
Max age
70 Years
Healthy volunteers
No
Inclusion Criteria:
* Voluntarily participate in this study and sign the informed consent form;
* Age 18-70 years old;
* Primary debulking surgery for epithelial ovarian cancer (including neoadjuvant chemotherapy), with or without abdominal and distant metastasis (≥ IIB stage);
* Colonoscopy negative (no mucosal layer invasion);
* Preoperative imaging (enhanced pelvic MRI) assesses the tumor's involvement of the intestinal surface and/or major parts of the mesentery;
* Eastern Cooperative Oncology Group (ECOG) score \< 3;
* American Society of Anesthesiologists (ASA) score \< 3.
Exclusion Criteria:
* Has a history of other malignant tumors or is undergoing other anti-tumor treatments;
* Has severe underlying medical conditions that make surgery intolerable;
* Epithelial ovarian cancer diagnosed incidentally during emergency surgery;
* Participates in other clinical studies simultaneously;
* Secondary cytoreductive surgery for epithelial ovarian cancer;
* Patients who have received radiotherapy to the abdomen or pelvis before.
Primary outcome measure(s)
Progression-free survival(PFS) — Two years after the surgery Two years progression-free survival rate will be estimated, and 95% confidence intervals will be calculated.
Trial sites (1)
Facility
City
Region
Status
Second Affiliated Hospital, School of Medicine, Zhejiang University
Hangzhou
Zhejiang
Recruiting
More Second Affiliated Hospital, Zhejiang University, School of Medicine trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time.